{"disease":{"id":"resectable-pancreatic-carcinoma","name":"resectable pancreatic carcinoma"},"drugs":{"marketed":[{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04596865","title":"Recurrence After Whipple's (RAW) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT07252232","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06714604","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT04340141","title":"Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":358,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06958328","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":356,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT07081360","title":"Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":262,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT05083247","title":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":256,"lead_sponsor_name":"Erasme University Hospital","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04423731","title":"Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT02959879","title":"Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT04858334","title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02562716","title":"S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT02767557","title":"Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT05518903","title":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07280377","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Oncolytics Biotech","has_results":false},{"nct_id":"NCT04821284","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Flemming Forsberg","has_results":false},{"nct_id":"NCT03063554","title":"EUS BD vs ERCP TP for Pancreatic Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT07080021","title":"A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":119,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04481204","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05275075","title":"Identify microRNAs in Cachexia in Pancreatic Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Oklahoma","has_results":false},{"nct_id":"NCT04600063","title":"Isolation Procedure vs. Conventional Procedure During Distal Pancreatectosplenectomy for Pancreatic Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Wakayama Medical University","has_results":false},{"nct_id":"NCT04789486","title":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06649474","title":"Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT06135896","title":"Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT04005690","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06595160","title":"Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03823144","title":"Intravital Microscopy in Human Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06816914","title":"Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT04560712","title":"Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02595931","title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03368963","title":"TAS102 in Combination With NAL-IRI in Advanced GI Cancers","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02495896","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01053013","title":"Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"The Rogosin Institute","has_results":true},{"nct_id":"NCT05688215","title":"Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03257761","title":"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT07189195","title":"TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT03003078","title":"A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"OncoSil Medical Limited","has_results":false},{"nct_id":"NCT03095781","title":"Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05053971","title":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02178709","title":"A Phase II Study of Neoadjuvant FOLFIRINOX","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Indiana University","has_results":true},{"nct_id":"NCT07269626","title":"PULSAR in Systemic Therapy for Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03250273","title":"A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT05685602","title":"CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03273374","title":"Intraoperative Radiation Therapy for Resectable Pancreatic Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT01783171","title":"Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03251365","title":"Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Hospital General de Ciudad Real","has_results":false},{"nct_id":"NCT06361030","title":"Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07240766","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Zhejiang University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}